Stopped: Impossibility of supplying the medication in research of the study by the pharmaceutical company that gave it to the trial
Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Sustained virological response
Timeframe: 12 weeks post-treatment